Cloud Capital Management’s ImmunityBio IBRX Stock Holding History

Cloud Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9	Closed	–	–	749
2025 Q3	$0	Buy	+9	New	+$23	﹤0.01%	1239

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Cloud Capital Management's IBRX Position: Q4 2025 in Review

Cloud Capital Management sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 9 shares.

Cloud Capital Management first reported a position in IBRX in Q3 2025 and held it in 1 quarter. The position peaked at $0 in Q3 2025. 278 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

Cloud Capital Management reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
Cloud Capital Management sold 9 ImmunityBio shares in Q4 2025.
Cloud Capital Management first reported a position in ImmunityBio in Q3 2025 and held it in 1 quarter.
Cloud Capital Management's ImmunityBio position peaked at $0 in Q3 2025.
278 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on Cloud Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.